CUREVAC N.V. O.N.
Commented by André Will-Laudien on July 23rd, 2021 | 11:37 CEST
CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?
Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...
Read
Commented by Nico Popp on July 20th, 2021 | 13:42 CEST
Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year
Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.
Read
Commented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
Read
Commented by Carsten Mainitz on July 12th, 2021 | 10:07 CEST
CureVac, XPhyto Therapeutics, Paion - Where are the turning points?
"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?
Read
Commented by André Will-Laudien on July 6th, 2021 | 13:49 CEST
Defence Therapeutics, CureVac, BioNTech - Successful therapy, earn billions!
Since we have a large number of health-threatening issues on the table, there are just as many biotech and pharma companies that have taken up the cause of researching and combating them. Many of them are publicly traded or in the early stages of venture funding. Investors are spoiled for choice; besides good analysis, they need a fair amount of intuition and luck to find the right stock that will truly become a 500-percenter. The cancer research company CEL-SCI recently disappointed, as did the COVID vaccine expert CureVac - both shares ended in a price disaster. The question remains - which horses are the right ones?
Read
Commented by André Will-Laudien on July 1st, 2021 | 10:41 CEST
CureVac, Barrick Gold, Troilus Gold - Now it is important to keep your nerves!
The bull market is maturing a bit more every day. It is no longer young - because it has been running steadily since 2015. Admittedly, it stuttered a bit in March 2020, but the subsequent recovery was all the more violent. There are long-term fundamental trends, so-called megatrends, such as digitalization or e-mobility. At present, we can assume that the mining industry will also boom again in contrast to the crypto world. That is because the medium-term parameters here match the current economic trends. Here is a small selection of well-positioned stocks.
Read
Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST
CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!
Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?
Read
Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST
CureVac, Cardiol Therapeutics, Bayer - Where we go from here
Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.
Read
Commented by André Will-Laudien on June 18th, 2021 | 12:49 CEST
CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!
How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.
Read
Commented by Nico Popp on June 15th, 2021 | 13:15 CEST
CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio
Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.
Read